Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Matritech (NASDAQ - NMPS) -- Ignore unavailable to you. Want to Upgrade?

To: John McDonald who wrote (522)	12/20/1997 6:28:00 PM
From: Wesley0428	Read Replies (1) \| Respond to of 849

Bayer has an option to the rights to develop an automated cervical cancer screen (pap smear) test based on NMPS technology. IMII has an automated microscopic system already on the market for performing similar laboratory tests, with a half dozen FDA approved procedures, but no Pap Smear as far as I know Bayer is in discussions with IMII about one of three things: -OEMing their automated microscopic test system -Using their automated slide prep technology (this could speed up the development of Bayer's own automated test system) -Jointly developing an exciting new test utilizing IMII's microscopic test system Any of these three could be related to Bayer's option with NMPS and would be very positive in terms of which way Bayer is leaning with regard to exercising their option for the cervical test and the likely timing (faster) of developing such a test. On the other hand, it could have absolutly nothing to do with the cervical test option. Just thought it was worth mentioning. Happy holidays to all, I'm Off2Aruba for a week.